Enzymotec, a leader in the world of premium omega products, presents a new and unique platform. As an expert in lipid technologies, Enzymotec explores and develops different ways to supply complete nutrients with better delivery system. A recent clinical study conducted by Enzymotec proved that fatty acids attached to phospholipids improve the absorption of omega-3 into the red blood cells (RBC) and increase the omega-3 index (Ramprasath VR, Lipids in Health and Disease 2013) more efficiently than triglyceride based oil. Enzymotec's unique approach addresses the entire human life cycle from infancy to old age. This unique approach leads to the development of a collection of premium omega products that can be distinguished for different clinical benefits.
Omega PC™ introduces a new premium, innovative line of omega-3 products within the Omega premium platform. Omega PC is a wild, cold fish extract, containing omega-3 fatty acids bound to phospholipids and triglycerides to better preserve the natural nutrients found in fish and enhance their broad impact on general health.
Dr. Ariel Katz, president and chief executive officer of Enzymotec Ltd., said: "The existing omega-3 market suffers from increased commoditization and lack of innovation, Omega PC is an innovative product in the omega-3 category that brings new benefits to the consumer. Enzymotec, with its wide expertise, is enthusiastic to offer our B2B customers a new world of opportunity to address their customers' needs and introduce the innovative Omega PC category with wide line of products to the Omega-3 premium consumer."